This protocol is judged by an institutional critique board, an unbiased group that assessments any medical trials involving humans. If a review includes a Schedule I drug, after the board approves the protocol as moral, the scientists really need to apply for an investigational new drug (IND) selection through the FDA.Some scientists and businesse